Description: CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. The company was founded in 2017 and is based in Houston, Texas.
Home Page: www.cnspharma.com
CNSP Technical Analysis
2100 West Loop South
Houston,
TX
77027
United States
Phone:
800 946 9185
Officers
| Name | Title |
|---|---|
| Mr. John Michael Climaco Esq., J.D. | Chairman, CEO & Pres |
| Mr. Christopher S. Downs CPA, CTP, FP&A | Chief Financial Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer |
| Dr. Waldemar Priebe Ph.D. | Founder |
| Dr. Donald H. Picker Ph.D. | Chief Science Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4006 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-11-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |